---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-081792"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2024-09-25T23:59:59+00:00"
generated_at: "2026-05-31T01:55:23.781363+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CERo raises $1.2M, CEO and CTO resign; CER-1236 on clinical hold

## Summary
- CEO Brian Atwood resigns effective no later than Sep 30, 2024; CTO Daniel Corey resigns immediately.
- Chris Ehrlich appointed interim Chairman and CEO; board searching for permanent replacement.
- Raised ~$1.2M via private placement of Series C preferred stock and warrants at $1,000/share.
- CER-1236 remains on clinical hold; Type A meeting with FDA requested to address two questions.
- CFO Charles Carter also stepping down; cost reductions being implemented.

## SEC filing metadata
- accession: 0001213900-24-081792
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2024-09-25T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/ea0215346-8k_cerothera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-081792
- JSON: https://secwatch.observer/filing/0001213900-24-081792.json
- Plain text: https://secwatch.observer/filing/0001213900-24-081792.txt

## Key facts
- Executive change
  Daniel Corey resigned as Chief Technology Officer at CERO THERAPEUTICS HOLDINGS, INC..
  - Action: resigned
  - Role: Chief Technology Officer
  source text: On September 23, 2024, the Company’s Chief Technology Officer and director, Daniel Corey, informed the Board of his resignation as Chief Technology Officer and director, effective immediately, to accept a new position on the faculty of the University of California, San Francisco.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm
- Executive change
  Chris Ehrlich was appointed as Interim Chairman and Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..
  - Action: appointed
  - Role: Interim Chairman and Chief Executive Officer
  source text: Chris Ehrlich, the Vice Chairman of the Board, agreed to serve as Interim Chairman and Chief Executive Officer while the Board searches for a permanent replacement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm
- Executive change
  Daniel Corey resigned as director at CERO THERAPEUTICS HOLDINGS, INC..
  - Action: resigned
  - Role: director
  source text: On September 23, 2024, the Company’s Chief Technology Officer and director, Daniel Corey, informed the Board of his resignation as Chief Technology Officer and director, effective immediately, to accept a new position on the faculty of the University of California, San Francisco.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm
- Executive change
  Brian G. Atwood resigned as Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On September 22, 2024, the Company’s Chairman and Chief Executive Officer, Brian G. Atwood, informed the Board of his resignation as Chief Executive Officer, effective at a date to be determined, which shall be no later than September 30, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.